Literature DB >> 19724288

Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.

Qingmin Guo1, Guangming Wang, Shobu Namura.   

Abstract

Fibrates, one group of peroxisome proliferator-activated receptor (PPAR) activators, are lipid lowering drugs. Fibrates have been shown to attenuate brain tissue injury after focal cerebral ischemia. In this study, we investigated the impact of fenofibrate on cerebral blood flow (CBF) in male wild type and PPARalpha-null mice. Animals were treated for 7 days with fenofibrate and subjected to 2 h of filamentous middle cerebral artery occlusion and reperfusion under isoflurane anesthesia. Cortical surface CBF was measured by laser speckle imaging. Regional CBF (rCBF) in nonischemic animals was measured by (14)C-iodoantipyrine autoradiography. Fenofibrate did not affect rCBF and mean arterial blood pressure in nonischemic animals. In ischemic animals, laser speckle imaging showed delayed expansions of ischemic area, which was attenuated by fenofibrate. Fenofibrate also enhanced CBF recovery after reperfusion. However, such effects of fenofibrate on CBF in the ischemic brain were not observed in PPARalpha-null mice. These findings show that fenofibrate improves CBF in the ischemic hemisphere. Moreover, fenofibrate requires PPARalpha expression for the cerebrovascular protective effects in the ischemic brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19724288      PMCID: PMC2801771          DOI: 10.1038/jcbfm.2009.185

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

1.  Comparison of laser speckle and laser Doppler perfusion imaging: measurement in human skin and rabbit articular tissue.

Authors:  K R Forrester; C Stewart; J Tulip; C Leonard; R C Bray
Journal:  Med Biol Eng Comput       Date:  2002-11       Impact factor: 2.602

2.  WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.

Authors:  Robyn Cunard; Dennis DiCampli; D Clay Archer; Jennifer L Stevenson; Mercedes Ricote; Christopher K Glass; Carolyn J Kelly
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

3.  Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury.

Authors:  Tian-li Yue; Weike Bao; Beat M Jucker; Juan-li Gu; Anne M Romanic; Peter J Brown; Jianqi Cui; Douglas T Thudium; Rogely Boyce; Cynthia L Burns-Kurtis; Rosanna C Mirabile; Karpagam Aravindhan; Eliot H Ohlstein
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

4.  Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

Authors:  Dominique Deplanque; Patrick Gelé; Olivier Pétrault; Isabelle Six; Christophe Furman; Muriel Bouly; Stéphane Nion; Bernard Dupuis; Didier Leys; Jean-Charles Fruchart; Roméo Cecchelli; Bart Staels; Patrick Duriez; Régis Bordet
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

5.  Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

Authors:  Amy E Lovett-Racke; Rehana Z Hussain; Sara Northrop; Judy Choy; Anne Rocchini; Lela Matthes; Janet A Chavis; Asim Diab; Paul D Drew; Michael K Racke
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock.

Authors:  Salvatore Cuzzocrea; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Carmelo Muià; Achille P Caputi
Journal:  Shock       Date:  2004-10       Impact factor: 3.454

7.  Leukocyte-endothelium interactions during permanent focal cerebral ischemia in mice.

Authors:  Hiroharu Kataoka; Seong-Woong Kim; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2004-06       Impact factor: 6.200

8.  Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Authors:  Nicole S Wayman; Yoshiyuki Hattori; Michelle C McDonald; Helder Mota-Filipe; Salvatore Cuzzocrea; Babrbara Pisano; Prabal K Chatterjee; Christoph Thiemermann
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

9.  Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice.

Authors:  Hiroyasu Inoue; Xiao Fan Jiang; Takahiro Katayama; Shiho Osada; Kazuhiko Umesono; Shobu Namura
Journal:  Neurosci Lett       Date:  2003-12-11       Impact factor: 3.046

Review 10.  Cerebral microvessel responses to focal ischemia.

Authors:  Gregory J del Zoppo; Takuma Mabuchi
Journal:  J Cereb Blood Flow Metab       Date:  2003-08       Impact factor: 6.200

View more
  21 in total

1.  Gemfibrozil pretreatment affecting antioxidant defense system and inflammatory, but not Nrf-2 signaling pathways resulted in female neuroprotection and male neurotoxicity in the rat models of global cerebral ischemia-reperfusion.

Authors:  Fatemeh Mohagheghi; Leila Khalaj; Abolhassan Ahmadiani; Behrouz Rahmani
Journal:  Neurotox Res       Date:  2012-07-07       Impact factor: 3.911

Review 2.  Sex differences in the immune response to experimental stroke: Implications for translational research.

Authors:  Abby L Dotson; Halina Offner
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels.

Authors:  Guangming Wang; Xiaowei Liu; Qingmin Guo; Shobu Namura
Journal:  Brain Res       Date:  2010-09-21       Impact factor: 3.252

4.  Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.

Authors:  Thavarak Ouk; Sophie Gautier; Maud Pétrault; David Montaigne; Xavier Maréchal; Isabelle Masse; Jean-Christophe Devedjian; Dominique Deplanque; Michèle Bastide; Rémi Nevière; Patrick Duriez; Bart Staels; Florence Pasquier; Didier Leys; Régis Bordet
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

5.  Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice.

Authors:  Guangming Wang; Shobu Namura
Journal:  Neurosci Res       Date:  2011-02-16       Impact factor: 3.304

6.  Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats.

Authors:  Vivian Boshra; Amal M Moustafa
Journal:  J Mol Histol       Date:  2011-02-09       Impact factor: 2.611

7.  Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia.

Authors:  C Potey; T Ouk; O Petrault; M Petrault; V Berezowski; J Salleron; R Bordet; S Gautier
Journal:  Br J Pharmacol       Date:  2015-10-06       Impact factor: 8.739

8.  Neuroprotection after cerebral ischemia.

Authors:  Shobu Namura; Hiroaki Ooboshi; Jialing Liu; Midori A Yenari
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

9.  Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults.

Authors:  Ashley E Walker; Rachelle E Kaplon; Sara Marian S Lucking; Molly J Russell-Nowlan; Robert H Eckel; Douglas R Seals
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

10.  Indole-3-carbinol improves neurobehavioral symptoms in a cerebral ischemic stroke model.

Authors:  Pankaj Paliwal; Gaurav Chauhan; Deepa Gautam; Debabrata Dash; Shashikant C U Patne; Sairam Krishnamurthy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.